Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Cevidoplenib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 14 Feb 2024 Status changed from active, no longer recruiting to completed.
- 11 Apr 2021 According to European Clinical Trials Database, the trial is completed in Poland
- 21 Sep 2020 Planned End Date changed from 14 Apr 2020 to 1 Oct 2020.